Structure of the Analgesic μ-Conotoxin KIIIA and Effects on the Structure and Function of Disulfide Deletion

详细信息    查看全文

• 作者：Keith K. Khoo ; Zhi-Ping Feng ; Brian J. Smith ; Min-Min Zhang ; Doju Yoshikami ; Baldomero M. Olivera ; Grzegorz Bulaj ; Raymond S. Norton
• 刊名：Biochemistry
• 出版年：2009
• 出版时间：February 17, 2009
• 年：2009
• 卷：48
• 期：6
• 页码：1210-1219
• 全文大小：437K
• 年卷期：v.48,no.6(February 17, 2009)
• ISSN：1520-4995

文摘

μ-Conotoxin μ-KIIIA, from Conus kinoshitai, blocks mammalian neuronal voltage-gated sodium channels (VGSCs) and is a potent analgesic following systemic administration in mice. We have determined its solution structure using NMR spectroscopy. Key residues identified previously as being important for activity against VGSCs (Lys7, Trp8, Arg10, Asp11, His12, and Arg14) all reside on an α-helix with the exception of Arg14. To further probe structure−activity relationships of this toxin against VGSC subtypes, we have characterized the analogue μ-KIIIA[C1A,C9A], in which the Cys residues involved in one of the three disulfides in μ-KIIIA were replaced with Ala. Its structure is quite similar to that of μ-KIIIA, indicating that the Cys1−Cys9 disulfide bond could be removed without any significant distortion of the α-helix bearing the key residues. Consistent with this, μ-KIIIA[C1A,C9A] retained activity against VGSCs, with its rank order of potency being essentially the same as that of μ-KIIIA, namely, Na_V1.2 > Na_V1.4 > Na_V1.7 ≥ Na_V1.1 > Na_V1.3 > Na_V1.5. Kinetics of block were obtained for Na_V1.2, Na_V1.4, and Na_V1.7, and in each case, both k_on and k_off values of μ-KIIIA[C1A,C9A] were larger than those of μ-KIIIA. Our results show that the key residues for VGSC binding lie mostly on an α-helix and that the first disulfide bond can be removed without significantly affecting the structure of this helix, although the modification accelerates the on and off rates of the peptide against all tested VGSC subtypes. These findings lay the groundwork for the design of minimized peptides and helical mimetics as novel analgesics.